Purification of Human CD34+CD90+ HSCs Reduces Target Cell Population and Improves Lentiviral Transduction for Gene Therapy
Stefan Radtke, Dnyanada Pande, Margaret Cui, Anai M. Perez, Yan-Yi Chan, Mark Enstrom, Stefanie Schmuck, Andrew J. Berger, Tom Eunson, Jennifer E. Adair, Hans‐Peter Kiem
Abstract
cells resulted in up to 3-fold higher levels of engrafted gene-modified blood cells. These studies should have important implications for the manufacturing of patient-specific HSC gene therapy and gene-engineered cell products.
Topics & Concepts
CD90Genetic enhancementStem cellProgenitor cellBiologyCD34HaematopoiesisCell therapyHematopoietic stem cellTransduction (biophysics)PopulationImmunologyCell biologyMolecular biologyCancer researchGeneGeneticsMedicineEnvironmental healthBiochemistryVirus-based gene therapy researchCAR-T cell therapy researchSingle-cell and spatial transcriptomics